Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70)

Shinichiro Shirabe; Katsuya Yamazaki; Mariko Oishi; Keiko Arai; Noriharu Yagi; Manaka Sato; Masakazu Takeuchi; Takahito Kai; Hiroshi Maegawa

doi:10.1111/jdi.13922

Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70)

J Diabetes Investig. 2023 Jan;14(1):75-80. doi: 10.1111/jdi.13922. Epub 2022 Oct 21.

Authors

Shinichiro Shirabe¹, Katsuya Yamazaki², Mariko Oishi³, Keiko Arai⁴, Noriharu Yagi⁵, Manaka Sato⁶, Masakazu Takeuchi⁶, Takahito Kai⁶, Hiroshi Maegawa⁷

Affiliations

¹ H.E.C. Science Clinic, Kanagawa, Japan.
² Kawai Clinic, Ibaraki, Japan.
³ Oishi Clinic, Kyoto, Japan.
⁴ Arai Clinic, Kanagawa, Japan.
⁵ Yagi Medical Clinic, Okinawa, Japan.
⁶ Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K, Hyogo, Japan.
⁷ Yasu City Hospital, Shiga, Japan.

Abstract

We assessed the prescription patterns of oral antidiabetic drugs in Japanese patients with type 2 diabetes between 2002 and 2020 using data from the Computerized Diabetes Care database. Among 172,960 patients treated with oral antidiabetic drugs, both the sulfonylurea prescription rate and dose decreased from 2002 to 2020. Prescriptions of biguanides, dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors increased; their dose and dose frequency remained relatively stable. Trends in oral antidiabetic drug prescriptions changed over time, reflecting guideline recommendations and existing evidence.

Keywords: Diabetes mellitus, type 2; Hypoglycemic agents; Japan.

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Dipeptidyl-Peptidase IV Inhibitors* / therapeutic use
Drug Prescriptions
East Asian People
Humans
Hypoglycemic Agents / therapeutic use
Sulfonylurea Compounds / therapeutic use

Substances

Hypoglycemic Agents
Sulfonylurea Compounds
Dipeptidyl-Peptidase IV Inhibitors

Grants and funding

Eli Lilly Japan K.K.